Tajikistan State Supervision, Inspections and Liability: Authority Powers Guide

1. Key takeaways

State supervision in Tajikistan is implemented uniformly by the State Supervisory Authority for Pharmaceutical Activity; the law equips it with 10 powers and prescribes 5 supervision methods in Article 12(4). GRZAN points out the three items most closely tied to post-market device compliance: Article 9(3) (expert review), Article 9(7) (inspection of compliance with good pharmaceutical practice requirements) and Article 9(8) (carrying out registration and re-registration). Together with the inspection authority of Article 12(4)(1) over the rules on production, quality control, retail and wholesale, preparation and dispensing, storage and destruction, the scope of supervision extends from the pre-market stage through to the whole chain ending in disposal. The consequences of violations are uniformly directed by Article 48 to the legislation of the Republic of Tajikistan.

2. Legal basis

3. Expert insights

Insight 1: Article 9(7) lists conformity inspection against good pharmaceutical practice (GxP) as a statutory power of the supervisory authority. Read together with the standards list in Article 1(13) — GLP, GCP, GMP, GVP, GPP and GDP — the inspection scope of the supervisory authority is not limited to GMP but covers six families of standards. Companies must prepare inspection materials separately for each of the six.

Insight 2: Article 12(4)(1) extends the inspection scope to storage and destruction. The stages listed in this method include production, quality control, retail and wholesale, preparation and dispensing, storage and destruction, forming a closed supervision loop from production to disposal. This design echoes the transport, storage and destruction requirements of Article 27 and the liability provisions of Article 47(2) and (4).

Insight 3: Article 12(3) sets multiple sources for quality criteria. Quality is determined according to domestic quality normative documents, the national pharmacopoeia, other pharmacopoeias recognized by Tajikistan, and the normative documents of manufacturers and the relevant foreign authorities. Combined with Article 8(17), under which the Ministry of Health recognizes foreign pharmacopoeias and quality standards where necessary, foreign standards can be adopted, but only upon recognition.

Insight 4: Article 9(8) and Article 9(3) concentrate registration, re-registration and expert review in one body. The same authority performs both review and registration functions, so companies face a single window in communication; this simplifies the communication path, but it also means no inter-agency buffer exists between the review opinion and the registration decision.

Insight 5: the information disclosure of Article 44(5) and the liability provision of Article 48 form a double constraint. If inspection results lead to cancellation or a non-conformity finding, the related information will be disclosed, and the impact extends beyond the administrative penalty itself.

4. Practical recommendations

1. Prepare inspection materials separately for the six families of standards. Under Article 9(7) and Article 1(13), cover GLP, GCP, GMP, GVP, GPP and GDP in six areas.
2. Bring storage and destruction into the scope of internal audits. Under Article 12(4)(1), the internal audit must cover the complete chain from production to disposal.
3. Confirm that the foreign standards in use have been recognized. Under Article 12(3) and Article 8(17), the application of foreign pharmacopoeias and quality standards is conditional on recognition.
4. Build a single-window communication mechanism. Under Article 9(3) and (8), review and registration are handled by the same authority, so the communication strategy should be concentrated rather than dispersed.
5. Track public information channels. Under Article 44(5), search periodically for registration, cancellation and non-conformity announcements.

5. Verification checklist

• □ Confirmed that the supervisory body under Article 12(1) is the State Supervisory Authority for Pharmaceutical Activity
• □ Confirmed that Article 12(4) lists five supervision methods
• □ Confirmed that Article 9(7) authorizes inspection of compliance with good pharmaceutical practice
• □ Prepared inspection materials separately for the six families of standards (GLP/GCP/GMP/GVP/GPP/GDP)
• □ Brought storage and destruction into the scope of internal audits
• □ Confirmed that the foreign standards in use have been recognized by Tajikistan (Article 12(3) and Article 8(17))
• □ Established a single-window communication mechanism toward the supervisory authority
• □ Established a periodic search mechanism for public information under Article 44(5)

Regulatory information verified as of October 29, 2026.

In the Central Asia market, the core capabilities of GRZAN concentrate on three points. First, distinguishing the different legal positions of individual markets within the Eurasian Economic Union — Kazakhstan and Kyrgyzstan are full member states, where a national pathway and a Union pathway both exist; Uzbekistan is an observer state with only a national pathway; Tajikistan and Turkmenistan lie outside the Union framework and must proceed entirely under national procedures. Second, local authorized representative services, which may act as the statutory representative of manufacturers in these countries and assume registration submissions, regulatory communication and post-market reporting obligations. Third, quality system and testing support, assisting in establishing a quality management system that meets ISO 13485 requirements and connecting with locally accredited laboratory resources.

Business inquiries: info@grzanglobal.com